Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 19, 2025 15:40 ET | Source: Tevogen Bio Inc

Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans

WARREN, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today expressed its gratitude to the U.S. Department of Health and Human Services...
September 19, 2025 08:05 ET | Source: Imunon, Inc.

IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research

OVATION 3 pivotal Phase 3 trial is currently advancing IMNN-001, with several patients being treated LAWRENCEVILLE, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a...
September 17, 2025 09:00 ET | Source: NovalGen Ltd.

NovalGen to Begin World’s First Clinical Trial for a Self-Regulating Immunotherapy

Groundbreaking cancer therapy that self-inactivates when there is risk of toxicity approved by MHRA for entry into Phase I clinical trial
September 16, 2025 19:30 ET | Source: Nxera Pharma

Nxera Pharma and Cancer Research UK Announce First Patient Dosed in Phase 2a Trial of Investigational Cancer Immunotherapy HTL0039732

HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist being investigated to treat a wide range of solid cancers in combination with other immunotherapiesCancer Research UK’s...
September 16, 2025 08:30 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Building Breakthrough Portfolio Aimed at Transforming Cancer, Rare Disease Treatments

NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of...
September 12, 2025 11:51 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Highlights 2 Years of Clinical and Regulatory Advancements Across Late-Stage Pipeline

AGOURA HILLS, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) ("OTLC" or the "Company"), a clinical-stage biopharmaceutical company developing...
September 10, 2025 08:30 ET | Source: InvestorBrandNetwork (IBN)

IBN Initiates Coverage of Oncotelic Therapeutics Inc.

AUSTIN, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- via IBN – Oncotelic Therapeutics Inc. (OTCQB: OTLC), a clinical stage biopharmaceutical company developing transformative oncology and immunotherapy...
September 08, 2025 11:02 ET | Source: Research and Markets

Interferon Market by Indication, Interferon Type, Administration Route, End User, Product Type, Dosage Form and Region - Shares and Industry Forecast 2025-2030

Dublin, Sept. 08, 2025 (GLOBE NEWSWIRE) -- The "Interferon Market Forecast 2025-2030" has been added to ResearchAndMarkets.com's offering. The interferon market is entering a period of meaningful...
September 08, 2025 10:39 ET | Source: Research and Markets

Trends & Strategies in the $54 Billion PD-1 & PD-L1 Inhibitors Market 2025: Industry Revenues Will More Than Double by 2030

Dublin, Sept. 08, 2025 (GLOBE NEWSWIRE) -- The "PD-1 & PD-L1 Inhibitors Market Forecast 2025-2030" report has been added to ResearchAndMarkets.com's offering. The PD-1 & PD-L1 Inhibitors...
September 05, 2025 07:00 ET | Source: Medicenna Therapeutics Corp.

Medicenna to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

Medicenna will present and participate in one-on-one meetings at the H.C. Wainwright 27th Annual Global Investment Conference in New York City.